339 related articles for article (PubMed ID: 26859456)
1. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
Ham J; Costa C; Sano R; Lochmann TL; Sennott EM; Patel NU; Dastur A; Gomez-Caraballo M; Krytska K; Hata AN; Floros KV; Hughes MT; Jakubik CT; Heisey DA; Ferrell JT; Bristol ML; March RJ; Yates C; Hicks MA; Nakajima W; Gowda M; Windle BE; Dozmorov MG; Garnett MJ; McDermott U; Harada H; Taylor SM; Morgan IM; Benes CH; Engelman JA; Mossé YP; Faber AC
Cancer Cell; 2016 Feb; 29(2):159-72. PubMed ID: 26859456
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax-based Rational Combinations are Effective in Models of
Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
[TBL] [Abstract][Full Text] [Related]
3. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
4. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death.
Sagulenko V; Muth D; Sagulenko E; Paffhausen T; Schwab M; Westermann F
Carcinogenesis; 2008 Oct; 29(10):1869-77. PubMed ID: 18566016
[TBL] [Abstract][Full Text] [Related]
6. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G
PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863
[TBL] [Abstract][Full Text] [Related]
9. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
10. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
11. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
13. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
16. Catastrophic ATP loss underlies a metabolic combination therapy tailored for
Dalton KM; Lochmann TL; Floros KV; Calbert ML; Kurupi R; Stein GT; McClanaghan J; Murchie E; Egan RK; Greninger P; Dozmorov M; Ramamoorthy S; Puchalapalli M; Hu B; Shock L; Koblinski J; Glod J; Boikos SA; Benes CH; Faber AC
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762304
[No Abstract] [Full Text] [Related]
17. NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells.
Shoji W; Suenaga Y; Kaneko Y; Islam SM; Alagu J; Yokoi S; Nio M; Nakagawara A
Biochem Biophys Res Commun; 2015 Jun; 461(3):501-6. PubMed ID: 25896758
[TBL] [Abstract][Full Text] [Related]
18. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
19. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
Slack A; Lozano G; Shohet JM
Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]